tiprankstipranks
Trending News
More News >

Impedimed Director Increases Stake Through Fee Conversion

Story Highlights
  • Impedimed is in the medical tech industry, focusing on non-invasive devices.
  • Director Andrew Grant increased his shares through fee conversion, boosting stakeholder confidence.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Impedimed Director Increases Stake Through Fee Conversion

Confident Investing Starts Here:

Impedimed Limited ( (AU:IPD) ) has issued an update.

Impedimed Limited announced a change in the director’s interest, with Mr. Andrew Grant acquiring additional shares. The acquisition was a result of the issuance of shares in lieu of 30% of director fees for the quarter ended 31 December 2024, enhancing his total shareholding to 2,308,583 ordinary shares. This move signals a deeper alignment of the director’s interests with the company, potentially impacting stakeholder confidence positively.

More about Impedimed Limited

Impedimed Limited is a company involved in the medical technology industry, primarily focused on developing and providing non-invasive medical devices for measuring, monitoring, and managing fluid status and body composition.

YTD Price Performance: -2.50%

Average Trading Volume: 31,879

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $69.19M

For an in-depth examination of IPD stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1